MTOR and acute myeloid leukemia: DLD1- and HCT116-derived CM reduced the expression of pAKT, p4EBP1, and pERK1/2 (Figure 1C and Figure S1C), suggesting that the anticancer effect of CM in AML cells may be associated with the downmodulation of PI3K/AKT/mTOR and ERK signaling.